Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
2 reports, 2 independent
Updated Sep 3
Gone quiet
- Reports
- 2
- Developments
- 6
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GSK is submitting data to the FDA regarding potential expansion of its drug indications.Sub-event
GSK's drug validation process is being influenced by FDA guidance, with ties to the U.K. operations.1 source
- GSK has launched a competing ROS1 therapy, while Nuvation Bio Inc. presented relevant data at a major medical conference.Sub-event
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.Sub-event
- Harmony, IDEAYA, and Hoffmann-La Roche partnered to study combination therapy for pancreatic cancer using machine learning.Sub-event
GSK is involved in competitive challenges regarding lung cancer treatments while awaiting FDA decisions.1 source
Keep exploring
The entities involved
- FDA
-
GSK
British multinational pharmaceutical and biotechnology company
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- Experimental therapies require approval from the FDA.
- GSK announced positive results for lung cancer drugs. Separately, Andy Burnham is meeting executives to discuss growth plans, while oil prices rose due to strikes on Saudi infrastructure.
- Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
- GSK and Novartis are identified as major pharmaceutical companies.